In the future, ACTN1 and ACTN3 could be considered used as biomarkers and indicators for allo-HSCT in AML, if their significant prognostic value were to be confirmed in larger prospective cohorts. The gene discussed is ACTN1; the disease is acute myeloid leukemia.